Tryptamine Therapeutics Ltd
TYP
Company Profile
Business description
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Contact
C/o Bio101 Financial Advisory Pty Ltd
697 Burke Road, Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920475
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
50
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,374.00 | 82.20 | -0.97% |
| CAC 40 | 7,725.38 | 45.10 | -0.58% |
| DAX 40 | 23,163.86 | 77.21 | 0.33% |
| Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,977.73 | 266.99 | 1.51% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.25 | 93.36 | 0.76% |
| S&P 500 | 5,686.67 | 82.53 | 1.47% |
| S&P/ASX 200 | 8,157.80 | 80.20 | -0.97% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |